百诚医药：关于全资子公司申报的BIOS2242口服溶液获得临床试验批准通知书的公告

Core Viewpoint - Baicheng Pharmaceutical's wholly-owned subsidiary, Zhejiang Saimer Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug BIOS2242 oral solution [1] Group 1 - The clinical trial approval indicates a significant step forward for Saimer Pharmaceutical in the development of BIOS2242 [1] - The approval from NMPA is crucial for the advancement of the drug through the regulatory process [1]